| **First Author, Year**  **Trial Name** | **G1 (N)**  **G2 (N)** | | **Mortality, N (%)** | **Quality of Life** | | **Cognitive Impairment** | | **MVAs, N (%)** | **CV Events, N (%)** | **CBV Events, N (%)** | | **Heart Failure, N (%)** | **Headache, N (%)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Arias, 2005128 | Total (37)  nCPAP first (14)  Sham nCPAP first (13) | | 0 (0.0)  0 (0.0) | NR | | NR | | NR | NR | NR | | NR | NR |
| Ballester, 1999170 | CPAP (68)  Usual Care (37) | | 0 (0.0)  0 (0.0) | NHP domains:  Emotional Reaction, mean (SE)  Baseline  CPAP: 28.4 (3.3)  UC: 29.4 (5.0)  12 wks  CPAP: 17.0 (3.0)  UC: 26.4 (4.5)  Between groups p=0.080  Sleep, mean (SE)  Baseline  CPAP: 30.1 (3.3)  UC: 23.1 (3.8)  12 wks  CPAP: 18.1 (3.0)  UC: 16.0 (4.0)  Between groups p=0.183  Physical, mean (SE)  Baseline  CPAP: 24.2 (2.6)  UC: 25.0 (3.6)  12 wks  CPAP: 15.1 (2.1)  UC: 21.1 (3.2)  Between groups p=0.090  Continued from above row  Social isolation, mean (SE)  Baseline  CPAP: 14.2 (2.3)  UC: 13.2 (3.0)  12 wks  CPAP: 8.5 (1.8)  UC: 11.2 (3.4)  Between groups p=0.030  NHP Domains:  Pain, mean (SE)  Baseline  CPAP: 20.5 (3.3)  UC: 20.6 (4.0)  12 wks  CPAP: 14.8 (3.1)  UC: 15.1 (3.9)  Between groups p=0.940  Energy, mean (SE)  Baseline  CPAP: 34.3 (4.7)  UC: 23.2 (4.6)  12 wks  CPAP: 12.7 (3.3)  UC: 22.2 (5.0)  Between groups p<0.005 | | Daytime function, mean (SE)  Baseline  CPAP: 33.9 (1.3)  UC: 32.3 (1.7)  12 wks  CPAP: 24.2 (1.2)  UC: 29.7 (2.0)  Between groups p<0.005 | | NR | NR | NR | | NR | NR |
| Barbe, 2001130 | Total (55)  CPAP (29)  Sham CPAP (26) | | 0 (0.0)  0 (0.0) | FOSQ, mean (SE)  Baseline  CPAP: 102 (3)  Sham: 107 (3)  6 wks  CPAP 108 (2)  Sham: 110 (2)  Change from BL  CPAP: 7 (2)  Sham: 3 (3)  Between group: p>0.2  SF-36 PCS, mean (SE)  Baseline  CPAP: 49 (1)  Sham: 48 (1)  6 wks  CPAP: 51 (1)  Sham: 50 (1)  Change from BL  CPAP: 2 (1)  Sham: 1 (1)  Between group: p>0.2  SF-36 MCS, mean (SE)  Baseline  CPAP: 51 (2)  Sham: 50 (2)  6 wks  CPAP: 51 (2)  Sham: 52 (2)  Change from BL  CPAP Change: -1 (2)  Sham Change: 1 (2)  Between group: p>0.2 | | Hits on Steer Clear test, mean (SE) %  Baseline  CPAP: 5 (1)  Sham: 6 (2)  6 wks  CPAP: 4 (1)  Sham: 5 (2)  Change from BL  CPAP: -1 (1)  Sham:-1 (1)  Between group p>0.2  Also reported: WAIS digit symbols, block design, digit span, PASAT 1-4, Trail making test A & B, Wechsler memory scale | | NR | NR | NR | | NR | NR |
| Barbe, 2012172 | CPAP (357) Control (366) | | All-cause:\*  8 (2.2)  3 (0.8)  CVD-specific:  1 (0.3)  0 (0.0) | NR | | NR | | NR | Total:  19 (5.3)  19 (5.2)  CV† Hospitalizations:  17 (4.8)  11 (3.0)  Nonfatal myocardial infarction:  2 (0.6)  8 (2.2) | TIA:  2 (0.6)  5 (1.4)  Non-fatal stroke:  3 (0.8)  2 (0.5) | | 3 (0.8)  5 (1.4) | NR |
| Barnes,  2004173 | CPAP (97)  Placebo (98) | | 0 (0.0)  0 (0.0) | FOSQ mean score, mean (SE):  Baseline: 3.1 (0.1)  3.3 (0.1), p < 0.001  3.3 (0.1), p < 0.01  CPAP vs. Placebo p < 0.05 | | Reported: Word Pair Memory Recall; Logical Memory Test; Digit Span Backwards; Trailmaking B; Digit Symbol Substitution Task; COWAT; PVT; Stroop Color Association Test | | NR | NR | NR | | NR | NR |
| Craig, 2012174 | CPAP (195)  Standard Care (196) | | 1 (0.5)  0 (0.0) | MCS, Mean (SD)  Baseline:  48.2 (10.4)  46.6 (11.3)  24 weeks:  52.0 (9.8)  48.5 (11.0)  Between group difference:  2.6 (95% CI, 0.9 to 4.2; p=0.003)  EQ-5D score, Mean (SD)ǂ  Baseline:  0.80 (0.17)  0.75 (0.24)  24 weeks:  0.83 (0.19)  0.80 (0.22)  Between group difference:  +0.20 (95% CI, -0.03 to 0.06; p=0.43)  SAQLI, mean (SD)  Baseline:  4.9 (1.1)  4.8 (1.2)  24 weeks:  5.6 (1.0)  5.0 (1.3)  Mean change (SE)  0.7 (0.1)  0.2 (0.1)  Between group difference: p<0.0001 | | NR | | NR | Angina:  1 (0.6)  3 (1.7)  MI:  0 (0.0)  0 (0.0)  PVD:  2 (1.2)  1 (0.6)  AF:  6 (3.5)  7 (4.1) | TIA:  1 (0.6)  0 (0.0)  Stroke:  0 (0.0)  0 (0.0) | | NR | NR |
| Durán-Cantolla, 2010137 | CPAP (169)  Sham (171) | | 0 (0.0)  0 (0.0) | EuroQol, mean (SD) at baseline, 6 wks, 12 wls  CPAP 69 (15), 74 (14),§ 76 (16)‖  Sham CPAP 72 (17), 72 (16), 73 (15) | | | NR | NR | NR | NR | | NR | NR |
| Egea, 2008138 | CPAP¶ (35)  Sham CPAP (38) | | 0 (0.0)  1 (2.6) | OSA Only  SF-36 – PCS, Mean (SE)  Baseline:  41.4 (2.0)  42.0 (2.1)  12 weeks  44.9 (1.8), p = 0.10  40.7 (2.1), p = 0.41  Between group p=NS  SF-36 – MCS, Mean (SE)  Baseline:  46.4 (3.0)  45.8 (2.7)  12 weeks  48.8 (2.3), p = 0.40  48.7 (2.2), p = 0.27  Between group p=NS | | | NR | NR | Angina  0 (0.0)  1 (2.6) | NR | | NR | NR |
| Engleman, 1994216 | CPAP first (17)  Oral placebo first (15) | | 0 (0.0)  0 (0.0) | NHP-2,  4 wks:  4.9 (SE 0.9)  7.9 (SE 0.9)  Between groups p=0.002  CPAP > placebo (p<0.05) for social life, sex life, and ability to carry out domestic chores | | | Mental Flexibility (Trailmaking B)  66 (SE 5)  75 (SE 5)  Between groups P= 0.02  Coding efficiency (Digit symbol substitution)  52 (SE 2)  51 (SE 2)  Between groups P= 0.05  Vigilance (Steer Clear, N objects hit)  76 (SE 5)  81 (SE 6)  Between groups P= 0.01  IQ decrement score  4.0 (SE 2.1)  7.2 (SE 2.0)  Between groups P= 0.04  Concentration (PASAT 2)  Between groups P= 0.02 but after adjustment for order effect, P=0.11 | NR | NR | NR | | NR | NR |
| Engleman, 1997217 | CPAP first (8)  Oral placebo first (8) | | 0 (0.0)  0 (0.0) | Nottingham Health Profile Part 2, total score  4 wks  3.8 (SE 1.1)  5.8 (SE 1.4)  Betw groups p=NS  Better compliers (mean 5 hrs/night), NHP Part 2 total score  4 wks  2.4 (SE 1.5)  6.8 (SE 2.5)  Betw groups p=0.03 | | | Reports IQ decrement, Trailmaking, SteerClear, PASAT2, RVIPT, reaction time, verbal fluency, BVRT.  Only significant changes on TrailMaking B no changes on other various cognitive functioning measures | NR | NR | NR | | NR | NR |
| Engleman, 1998175 | CPAP first (10)  Placebo (13) | | 0 (0.0)  0 (0.0) | NHP-2  Baseline, mean (SD)  8.0 (5.0)  4 wks, mean (SD)  5.8 (5.4)  6.3 (5.7)  Between group change:  -0.5 (95% CI, -2.5 to 1.5; p=NS) | | | No significant difference between groups on changes in the following:  30 min. SteerClear;TrailMaking B; WAIS-R performance IQ (Block Design and Digit Symbol Substitution);NART; RVIP;# 8-choice reaction time; PASAT;\*\* Verbal fluency; BVRT†† | NR | NR | NR | | NR | NR |
| Engleman, 1999176 | Total (37)  CPAP first (NR)  Oral Placebo first (NR) | | 0 (0.0)  0 (0.0) | NHP- 2 score, mean (SD)  Baseline: 10.5 (4.8)  4 wks CPAP: 6.1 (4.7)  4 wks placebo: 7.3 (5.2)  Between groups p = NS  SF-36 Domains only:  Physical Function  Baseline: 75 (27)  4 wks CPAP: 84 (22)  4 wks placebo: 83 (23)  Between groups p=NS  Mental health  Baseline: 64 (19)  4 wks CPAP: 79 (16)  4 wks Placebo: 75 (15)  Between groups p=NS  General Health  Baseline: 68 (21)  4 wks CPAP: 76 (19)  4 wks placebo: 74 (20)  Between groups p=NS | | | SteerClear (obstacles hit), mean (SD)  Baseline: 295 (183)  4 wks CPAP: 189 (156)  4 wks placebo: 195 (158)  Between groups p=NS  Also reported  TrailMaking A, Trailmaking B,  Digit Symbol, Block Design, performance IQ, PASAT | NR | NR | NR | | NR | 0 (0.0)  3 (8.8) |
| Faccenda, 2001177 | Total (71)  CPAP first (35)  Pbo capsule first (36) | | 0 (0.0)  0 (0.0) | FOSQ total, mean change from baseline (SE):  12.4 (0.5)  11.6 (0.7)  P=0.010 | | | NR | NR | NR | NR | | NR | NR |
| Gottlieb, 2014178  HeartBEAT | CPAP+ usual care (106)  Usual care alone (106) | | 0 (0.0)  0 (0.0) | NR | | | NR | 0 (0.0)  0 (0.0) | Unstable angina:  0 (0.0)  1 (0.9)  MI:  0 (0.0)  1 (0.9)  PCI for worsening angina:  0 (0.0)  1 (0.9  AF:  1 (0.9)  0 (0.0)  Arrhythmiaǂǂ  0 (0.0)  1 (0.9) | Stroke:  0 (0.0)  1 (0.9) | | NR | NR |
| Haensel, 2007139 | CPAP (25)  Sham CPAP (25) | | 0 (0.0)  0 (0.0) | NR | | | NR | NR | NR | NR | | NR | NR |
| Hoyos, 2012140 | CPAP (34)  Sham CPAP (31) | | All-cause:  0 (0.0)  0 (0.0) | NR | | | NR | NR | NR | NR | | NR | NR |
| Jenkinson, 1999142  Hack, 2000143 | | CPAP (54)  Subtherapeutic CPAP (53) | 0 (0.0)  0 (0.0) | SF-36 MCS, mean (SD)  Baseline:  44.8 (10.4)  43.5 (10.7)  4 wks:  55.4 (7.0)  47.8 (10.1)  Between group change: p=0.002  SF36 PCS, mean (SD):  Baseline:  43.7 (11.6)  42.6 (10.1)  4 wks:  49.4 (10.1)  45.5 (10.4)  5.7 (NR); p<0.001  2.9 (NR); p=0.007  Between group change: p=0.080 | | | Measures of driving simulation | NR | NR | NR | | NR | NR |
| Kushida, 2012145 Batool-Anwar, 2016288  APPLES | | CPAP (558)  Sham (547) | 2 (0.4)  2 (0.4) | SAQLI, mean (SD)  Compliance < 4 hours  Baseline:  4.7 (0.8)  4.6 (0.8)  6 months:  4.7 (0.8)  4.6 (1.0)  Between-group change: p≥0.05  Compliance > 4 hours  Baseline:  4.7 (0.8)  4.8 (0.8)  6 months:  5.0 (0.7)  4.9 (0.7)  Between-group change: p<0.05 | | | No difference between groups on multiple measures of neurocognitive function (Pathfinder NumberTest, Buschke Selective Reminding Test,  Sustained Working Memory Test) | 10 (1.8)  11 (2.0) | CV events reported as “adverse events” but not defined: 31 (5.6)  29 (5.3) | NR§§ | | NR | NR |
| Lam, 2007180 | | CPAP (34)  Usual care (33) | 0 (0.0)  0 (0.0) | SAQLI total score, mean (SE)  Baseline:  5.0 (0.1)  5.1 (0.1)  10 weeks:  5.5 (0.1)  5.0 (0.1)  Between group difference: 0.77 (-1.5 to 0.4); p=0.04  SF36, mean (SEM); p-val of within group change from BL; between group change from BL vs. usual care  Physical function domain, Baseline  84.7 (2.2)  82.3 (2.6)  10 weeks  88.2 (1.7); p<0.05; p<0.05  78.9 (3.6)  General health domain,  Baseline  48.3 (3.1)  51.2 (3.3)  10 weeks  58.9 (3.3); p<0.05; p=NS  54.8 (3)  Mental health domain,  Baseline  66.8 (2.5)  65.6 (2.5)  10 weeks  71.8 (2.8); p=NS; p=NS  68.0 (2.5) | | | NR | NR | NR | NR | | NR | NR |
| Lee, 2011147 | | Total (38)  CPAP (17)  Sham CPAP (21) | 0 (0.0)  0 (0.0) | NR | | | Measured:  WAIS-III; Digit Symbol; Digit Span; Letter-Number Sequencing; Symbol Search; Brief Visuospatial Memory Test-Rev; Hopkins Verbal Learning Test-Rev; Trail Making A/B; Digit Vigilance; Stroop Color-Word; Word Fluency | NR | NR | NR | | NR | NR |
| Lim, 2007215 | | Total (46)  nCPAP (17)  Sham CPAP (14) | NR | NR | | | Reports multiple cognitive function outcomes | NR | NR | NR | | NR | NR |
| Malow, 2008150 | | Total (35)  CPAP (22)  Sham CPAP (13) | 0 (0.0)  0 (0.0) | NR | | | NR | NR | NR | NR | | NR | NR |
| Marshall, 2005151 | | Total (31)  CPAP first (15)  Sham first (16) | 0 (0.0)  0 (0.0) | | FOSQ total, mean (SE):  Baseline: 12.6 (0.3)  13.6 (0.3), p < 0.01  13.3 (0.3), p=ns  Btwn groups diff= 0.3 (-0.5 to 1.1)  **SF36 domains**  Mental health  Baseline: 75 (3)  77 (2) p=NS  80 (2) p <0.05  Btwn groups diff=-3 (-10 to 3)  Physical functioning  Baseline: 82 (3)  81 (2) p=NS  80 (2) p=NS  Btwn groups diff=1 (-3 to 6)  General health  Baseline: 74 (3)  76 (2) p=NS  76 (2) p=NS  Btwn groups diff=0 (-6 to 7) | | Psychomotor vigilance task:  Mean (SE) reaction time (ms):  Baseline: 264 (5)  266 (5) p=NS  259 (5) p=NS  Betw groups diff=7  (-7 to 20)  Mean (SE) lapses (>500 ms reaction time):  Baseline: 1.3 (0.3)  3.2 (0.7) p=NS  3.3 (0.7) p=NS  Betw groups diff=0.4  (-0.7 to 1.4)  Errors, mean (SE):  Baseline: 2.8 (0.5)  3.2 (0.7) p=NS  3.3 (0.7) p=NS  Betw groups diff=  -0.1 (-2.0 to 1.9) | NR | Non-fatal MI: 0 (0.0)  1 (3.2) | NR | | NR | NR |
| McMillan, 2014182 | | Total (278)  CPAP + BSC (140)  BSC only (138) | NR | | SAQL, baseline, mean (SD)  4.8 (1.2)  4.7 (1.2)  12 weeks, mean (SD)  5.3 (1.1)  5.0 (1.1)  between groups p=0.005  52 weeks, mean (SD)  5.5 (1.1)  5.1 (1.1)  between groups p=0.001  SF-36 reported in Figure only; authors report improvement on the energy and vitality subscales | | No difference between groups in cognitive function measures:  Digit symbol substitution  Trail Making B  Simple reaction time | 52 weeks:  2 (3.0)  1 (1.0) | 52 weeks:  MI  3 (2.1)  0 (0.0)  New Angina  2 (1.4)  3 (2,2)  New A-fib  6 (4.3)  12 (8.7)  New PVD  1 (0.3)  0 (0.0)  All  12 (4.3)  15 (10.1)  betw groups for all CV events p=0.72 | 52 weeks:  Stroke  0 (0.0)  0 (0.0)  “Mini-stroke”  1 (0.3)  2 (1.4)  between groups for al adverse CV events p=0.72 | | NR |  |
| Montserrat, 2001154 | | CPAP (24)  Placebo CPAP (24) | 0 (0.0)  0 (0.0) | | FOSQ total, mean change from baseline (SD):  25.0 (NR); P<0.001  14.5 (NR); P=0.008  Between groups P=0.12  SF36 MCS, mean change from baseline (SD):  1.32 (NR); P=0.61  4.92 (NR); P=0.006  Between groups P=0.52  SF36 PCS, mean change from baseline (SD):  4.18 (NR); P=0.002  1.62 (NR); P=0.36  Between groups P=0.23 | | NR | NR | NR | NR | | NR | NR |
| Neikrug, 2014155 | | CPAP (19)  Sham CPAP (19) | 0 (0.0)  0 (0.0) | | NR | | NR | NR | NR | NR | | NR | NR |
| Nguyen, 2010157 | | nCPAP (10), sham CPAP (10) | 0 (0.0)  0 (0.0) | | NR | | NR | NR | NR | NR | | NR | NR |
| Phillips, 2011161 | | Total (38)  CPAP first (18)  Sham CPAP first (19) | NR | | FOSQ total, mean (SD):  Baseline:  15.2 (3.1)  8 week, mean (SE):  16.0 (0.53)  16.7 (0.52)  Between groups P=0.056 | | NR | NR | NR | NR | | NR | NR |
| Redline, 1998183 | | Total (111)  nCPAP (59)  Conservative therapy (52) | 0 (0.0)  0 (0.0) | | SF-36 Energy/fatigue subscore, mean (SD)  Baseline:  51.7 (19.8)  58.3 (19.0)  Change from BL to 8-12 wks  10.3 (17.8)  2.3 (16.8)  Between groups p<0.05 | | NR | NR | NR | NR | | NR | NR |
| Robinson, 2006162 | | Total (35)  CPAP first (18)  Sham first (17) | 0 (0.0)  0 (0.0) | | NR | | NR | NR | NR | NR | | NR | NR |
| Ruttanaumpawan, 2008184 | | CPAP (12)  No treatment (12) | 0 (0.0)  0 (0.0) | | NR | | NR | NR | NR | NR | | (All pts had HF) | NR |
| Siccoli, 2008164 | | CPAP (51)  Sham CPAP (51) | 0 (0.0)  0 (0.0) | | SF-36 PCS,‖‖ Mean (SD)  Baseline  62.0 (20.0)  69.4 (21.5)  4 weeks  70.8 (18.5) P<0.0001  70.0 (18.8) P=0.68  Between groups P=0.010  SF-36 MCS, Mean (SD)  Baseline  62.2 (20.2)  64.8 (21.2)  4 weeks  76.8 (16.2) P<0.0001  68.6 (22.7) P=0.17  Between groups P=0.002  SAQLI , Mean (SD)  Baseline  3.5 (1.0)  3.8 (1.1)  4 weeks  4.4 (1.1) P<0.0001  3.8 (1.6) P=0.65  Between groups P=0.001 | | NR | NR | NR | | NR | NR | NR |
| Smith, 2007163 | | Total (26)  CPAP first (11)  Sham first (13) | 0 (0.0)  0 (0.0) | | MLHF  Baseline: 38 (27)  G1: 36 (29)  G2: 34 (28)  Between groups difference 1.0 (-4.3 to 6.4) P=0.70  SF36 PCS  Baseline: 34 (16)  G1: 34 (14)  G2: 35 (14)  Between groups difference  -1.0 (-3.6 to 1.6) P=0.43  SF36 MCS  Baseline: 51 (10)  G1: 49 (12)  G2: 50 (11)  Between groups difference  -0.5 (-4.2 to 3.2) P=0.79 | | NR | NR | NR | NR | | NR | NR |
| Weaver, 2012166 | | Total (281)  CPAP (141)  Sham CPAP (140) | 0 (0.0)  0 (0.0) | | FOSQ total, unadj mean change from BL (SD):  0.98 (2.89) p=0.0005  -0.14 (2.61) p=0.57  Adj mean change from BL (SD):  0.89 (NR)  -0.06 (NR)  Adj diff in mean change (SE);  0.95 (0.34)  Between groups p=0.006  SF-36, PCS  Adj mean change from BL:  3.89  0.04  Adj between group difference in mean change from BL (SE):  3.85 (1.17)  95% CI, 1.53-6.17  p=0.001  SF-36, MCS  Adj mean change from BL:  3.07  2.21  Adj between group difference in mean change from BL (SE):  0.86 (1.42)  95% CI, -1.95 -3.67  p=0.546 | | NR | NR | NR | NR | | NR | NR |
| West, 2007168 | | CPAP (20)  Sham CPAP (22) | NR | | SAQLI, mean (SD)  Baseline  4.3 (1.1)  4.4 (0.9)  Change from BL at 12 wks:  +0.8 (1.0)  +0.03 (1.2)  Between-group difference (95% CI):  0.77 (-1.5 to 0.04); p=0.04 | | NR | NR | 1 CPAP patient (5%) had emergency cardiac surgery | NR | | NR | NR |

\* Footnote: For all-cause mortality, the authors also report an incidence density ratio: 2.6 (95% CI, 0.70-11.8; P=0.16)

† Hospitalizations were for unstable angina or arrhythmias.

ǂ Authors also report the EQ-5D Health Status (Visual Analogue Score); there were no differences between groups in the total score (p=0.095).

§ P<0.001 compared with baseline; effect size (SD units) 0.31

‖ P<0.001 compared with baseline; effect size (SD units) 0.38; EuroQol scores improved significantly only in the CPAP group

¶Sample size includes some patients who had central sleep apnea.

# Rapid visual information proecessing

\*\* 2 second presentation rate

†† Benton visual retention test

ǂǂ Per authors, one person in the control group developed “unspecified tachyarrhythmia requiring hospitalization.”

§§ Authors report counts for neurological “adverse events” but do not specify how these were measured or defined: CPAP 36 events (6.5%) versus Sham 32 events (5.9%)

‖‖ Authors also report a score for the PCS and MCS components of the SF-12; results are similar to those seen on the SF-36.

**Abbreviations:** adj=adjusted; AF=atrial fibrillation; APPLES=Apnea Positive Pressure Long-term Efficacy Study; BL=baseline; BSC=best supportive care; btwn=between; BVRT=Benton Visual Retention Test; CBV=cerebrovascular; CI=confidence interval; COWAT=Controlled Oral Word Association Test; CPAP=continuous positive airway pressure; CV=cardiovascular; CVD=cardiovascular disease; EQ=EuroQoL; FOSQ=Functional Outcomes of Sleep Questionnaire; G=group; HeartBEAT=Heart Biomarker Evaluation in Apnea Treatment; HF=heart failure; MCS=Mental Component Score of the SF-36; IQ=intelligence quotient; MI=myocardial infarction; MLHF=Minnesota Living with Heart Failure; ms=milliseconds; MVA=motor vehicle accident; N=sample size; NART=National Adult Reading Test**;** NHP=Nottingham Health Profile; nCPAP=nasal continuous positive airway pressure; NR=not reported; NS=not significant; PASAT=Paced Auditory Serial Addition Test; PCI=percutaneous coronary intervention; PCS=Physical Component Score of the SF-36; pts=patients; PVD=peripheral vascular disease; PVT=psychomotor vigilance test; RVIP=Rapid Visual Information Processing; SAQLI=Sleep Apnea Quality of Life Index; SE=standard error; SF-36=36-Item Short Form Health Survey; TIA=transient ischemic attack; UC=usual care; WAIS=Wechsler Adult Intelligence Scale; wks=weeks.